Modified Lincosamide Analogs for Drug-Resistant Bacteria
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Emerging resistance to existing antibiotics, particularly against Gram-negative bacteria, necessitates the development of new lincosamides with improved therapeutic efficacy and broad-spectrum activity to address infections caused by drug-resistant pathogens.
Innovation Solution
Development of lincosamide analogs with modified northern and amino-acid regions, including a novel heterocyclic moiety to constrain the binding conformation, enhancing target engagement and reducing metabolic degradation, thereby increasing potency against both Gram-positive and Gram-negative pathogens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If clindamycin is used to treat bacterial infections, then antibacterial activity is achieved, but metabolic degradation by hepatic cytochrome P450 enzymes reduces therapeutic efficacy
Solution Approach 1:
The patent modifies the glycosidic bond configuration from the natural clindamycin structure to an analog with altered stereochemistry at the glycosidic linkage. This parameter change in molecular structure reduces recognition by hepatic cytochrome P450 enzymes, thereby decreasing metabolic degradation and improving therapeutic efficacy.
2Reliability
If lincosamides are used to treat bacterial infections, then protein synthesis inhibition is achieved, but resistance develops through methylation of the 23s binding site
Solution Approach 1:
The patent introduces asymmetric modifications at specific positions in the lincosamide molecule (positions 2, 3, and 6) with different substituents that create steric hindrance and electronic effects. This asymmetric structure prevents methylation of the 23s ribosomal binding site by resistant bacteria, thereby maintaining antibacterial activity against resistant strains.
Solution Approach 2:
The patent applies local modifications specifically at the northern (glycosidic) and amino-acid (southern) regions of the lincosamide molecule. These localized changes enhance binding affinity to the 23s ribosomal subunit while avoiding recognition by resistance mechanisms, thereby maintaining efficacy against resistant pathogens.
3Reliability
If clindamycin is used to treat infections, then bacterial growth inhibition is achieved, but pseudomembranous colitis is caused by C. difficile overgrowth
Solution Approach 1:
The patent modifies the glycosidic bond stereochemistry and introduces heterocyclic moieties that change the pharmacokinetic profile and selective pressure. These parameter changes reduce the promotion of C. difficile overgrowth while maintaining activity against pathogens causing the original infection.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified lincosamide compounds demonstrate potent anti-microbial activity against a range of pathogens, including drug-resistant bacteria, offering improved therapeutic efficacy and potential treatment options for infections such as Staphylococcus, Streptococcus, and other bacterial species.
Implementation Method 1
They bind to the 23s portion of the 50S subunit of bacterial ribosomes and cause premature dissociation of the peptidyl-tRNA from the ribosome
Implementation Method 2
The lincosamides are a class of antibiotics that prevent bacteria growth by interfering with the synthesis of proteins
Implementation Method 3
Clindamycin's primary degradation pathway in vivo is the 'first-pass' oxidation of its methyl thioglycoside by hepatic cytochrome P450 enzymes to form comparatively inactive clindamycin sulfoxide diastereomers
Data Source
AI summary
Provided are compounds useful for the treatment and prevention of infectious diseases. The compound structures are lincosamide analogs modified at the aminooctose (northern) and amino acid (southern) regions. Also provided are methods for preparing the lincosamide compounds, pharmaceutical compositions comprising the lincosamide compounds, and methods of treating infectious diseases using the disclosed lincosamide compounds.